In Vivo Prevalence of Beta-Amyloid Pathology and Alzheimer’s Disease Co-Pathology in Idiopathic Normal-Pressure Hydrocephalus—Association with Neuropsychological Features DOI Creative Commons
Efstratios‐Stylianos Pyrgelis, George P. Paraskevas, Vasilios C. Constantinides

и другие.

Biomedicines, Год журнала: 2024, Номер 12(8), С. 1898 - 1898

Опубликована: Авг. 20, 2024

Idiopathic normal-pressure hydrocephalus (iNPH) is a clinic-radiological neurological syndrome presenting with cognitive deficits, gait disturbances and urinary incontinence. It often coexists Alzheimer's disease (AD). Due to the reversible nature of iNPH when promptly treated, lot studies have focused on possible biomarkers, among which are cerebrospinal fluid (CSF) biomarkers. The aim present study was determine rate beta-amyloid pathology AD co-pathology by measuring CSF namely, amyloid beta 42 40 amino acids (Aβ42), Aβ42/Aβ40 ratio, total Tau protein (t-Tau) phosphorylated at threonine 181 (p-Tau), in cohort patients, as well investigate associations biomarkers neuropsychological profiles. Fifty-three patients were included study. Aβ42, Aβ40, t-Tau p-Tau measured duplicate double-sandwich ELISA assays. evaluation consisted Mini-Mental State Examination, Frontal Assessment Battery, Five-Word Test CLOX drawing tests 1 2. After statistical analysis, we found that rather common higher values levels, existence profile, associated more severe memory impairment patients. In conclusion, our has confirmed AD-co-pathology markers worse decline these

Язык: Английский

Targeting Human Glucocorticoid Receptors in Fear Learning: A Multiscale Integrated Approach to Study Functional Connectivity DOI Open Access
Simone Battaglia, Chiara Di Fazio,

Matteo Mazzà

и другие.

International Journal of Molecular Sciences, Год журнала: 2024, Номер 25(2), С. 864 - 864

Опубликована: Янв. 10, 2024

Fear extinction is a phenomenon that involves gradual reduction in conditioned fear responses through repeated exposure to fear-inducing cues. Functional brain connectivity assessments, such as functional magnetic resonance imaging (fMRI), provide valuable insights into how regions communicate during these processes. Stress, ubiquitous aspect of life, influences learning and by changing the activity amygdala, prefrontal cortex, hippocampus, leading enhanced and/or impaired extinction. Glucocorticoid receptors (GRs) are key stress response show dual function regulation: while they enhance consolidation memories, also facilitate Accordingly, GR dysregulation associated with anxiety mood disorders. Recent advancements cognitive neuroscience underscore need for comprehensive understanding integrates perspectives from molecular, cellular, systems levels. In particular, neuropharmacology provides neurotransmitter receptor systems, aiding investigation mechanisms underlying regulation potential therapeutic targets. A notable player this context cortisol, hormone, which significantly both memory reconsolidation Gaining thorough intricate interactions has implications terms addressing psychiatric disorders related stress. This review sheds light on complex between processes, emotions, their neural bases. endeavor, our aim reshape comprehension fear, stress, emotional well-being, ultimately development interventions.

Язык: Английский

Процитировано

35
Neural Correlates and Molecular Mechanisms of Memory and Learning DOI Open Access
Simone Battaglia, Alessio Avenanti, László Vécsei

и другие.

International Journal of Molecular Sciences, Год журнала: 2024, Номер 25(5), С. 2724 - 2724

Опубликована: Фев. 27, 2024

Memory and learning are essential cognitive processes that enable us to obtain, retain, recall information [...].

Язык: Английский

Процитировано

33
Neurodegeneration in Cognitive Impairment and Mood Disorders for Experimental, Clinical and Translational Neuropsychiatry DOI Creative Commons
Simone Battaglia, Alessio Avenanti, László Vécsei

и другие.

Biomedicines, Год журнала: 2024, Номер 12(3), С. 574 - 574

Опубликована: Март 5, 2024

Neurodegeneration poses a significant challenge for the fields of neuroscience and medicine, as it is underlying cause development advancement numerous neurodegenerative psychiatric disorders [...]

Язык: Английский

Процитировано

25
From Lab to Life: Exploring Cutting-Edge Models for Neurological and Psychiatric Disorders DOI Creative Commons
Masaru Tanaka, László Vécsei

Biomedicines, Год журнала: 2024, Номер 12(3), С. 613 - 613

Опубликована: Март 8, 2024

Neuroscience, neurology, and psychiatry are rapidly evolving fields that aim to understand the complex mechanisms underlying brain function dysfunction, as well develop effective interventions for various neurological psychiatric disorders [...]

Язык: Английский

Процитировано

19
Innovation at the Intersection: Emerging Translational Research in Neurology and Psychiatry DOI Creative Commons
Masaru Tanaka, Simone Battaglia, Lydia Giménez‐Llort

и другие.

Cells, Год журнала: 2024, Номер 13(10), С. 790 - 790

Опубликована: Май 7, 2024

Translational research in neurological and psychiatric diseases is a rapidly advancing field that promises to redefine our approach these complex conditions [...]

Язык: Английский

Процитировано

19
A Decade of Dedication: Pioneering Perspectives on Neurological Diseases and Mental Illnesses DOI Creative Commons
Masaru Tanaka, László Vécsei

Biomedicines, Год журнала: 2024, Номер 12(5), С. 1083 - 1083

Опубликована: Май 13, 2024

Welcome to

Язык: Английский

Процитировано

17
Navigating the Neurobiology of Migraine: From Pathways to Potential Therapies DOI Creative Commons
Masaru Tanaka, Bernadett Tuka, László Vécsei

и другие.

Cells, Год журнала: 2024, Номер 13(13), С. 1098 - 1098

Опубликована: Июнь 25, 2024

Migraine is a debilitating neurological disorder characterized by recurring episodes of throbbing headaches that are frequently accompanied sensory disturbances, nausea, and sensitivity to light sound [...]

Язык: Английский

Процитировано

13
The Impact of C-3 Side Chain Modifications on Kynurenic Acid: A Behavioral Analysis of Its Analogs in the Motor Domain DOI Open Access
Diána Martos, Bálint Lőrinczi, István Szatmári

и другие.

International Journal of Molecular Sciences, Год журнала: 2024, Номер 25(6), С. 3394 - 3394

Опубликована: Март 16, 2024

The central nervous system (CNS) is the final frontier in drug delivery because of blood–brain barrier (BBB), which poses significant barriers to access most drugs their targets. Kynurenic acid (KYNA), a tryptophan (Trp) metabolite, plays an important role behavioral functions, and abnormal KYNA levels have been observed neuropsychiatric conditions. current challenge lies delivering CNS owing its polar side chain. Recently, C-3 chain-modified analogs shown cross BBB; however, it unclear whether they retain biological functions parent molecule. This study examined impact analogs, specifically, SZR-72, SZR-104, newly developed SZRG-21, on behavior. were administered intracerebroventricularly (i.c.v.), effects motor domain compared with those KYNA. Specifically, open-field (OF) rotarod (RR) tests employed assess activity skills. SZR-104 increased horizontal exploratory OF test at dose 0.04 μmol/4 μL, while SZR-72 decreased vertical doses 0.1 μL. In RR test, neither nor showed any differences skills either dose. Side chain modification affects affective performance behavior, as results show for first time. this study, we that alter emotional components such motor-associated curiosity emotions. Consequently, design necessitates development precise strategies traverse BBB paying close attention modifications

Язык: Английский

Процитировано

12
The Involvement of Antioxidants in Cognitive Decline and Neurodegeneration: Mens Sana in Corpore Sano DOI Creative Commons
Claudio Nazzi, Alessio Avenanti, Simone Battaglia

и другие.

Antioxidants, Год журнала: 2024, Номер 13(6), С. 701 - 701

Опубликована: Июнь 7, 2024

With neurodegenerative disorders being on the rise, a great deal of research from multiple fields is conducted in order to further knowledge and propose novel therapeutic interventions. Among these investigations, role antioxidants contrasting cognitive decline putting forward interesting promising results. In this review, we aim collect evidence that focused variety antioxidant-rich foods improving or stabilizing functions, memory, Alzheimer’s disease, most common disorder. Specifically, considered collected humans, either through longitudinal studies randomized, placebo-controlled ones, which evaluated performance, memory abilities, progression level neurodegeneration. Overall, despite between study protocols, cohorts participants involved, neuropsychological tests used, investigated antioxidants, there solid trend suggests properties may be helpful hampering older people. Thus, help future will elucidate neuroprotection lead development interventions take into account such findings provide more global approach treating disorders.

Язык: Английский

Процитировано

12
Ginkgo biloba: A Leaf of Hope in the Fight against Alzheimer’s Dementia: Clinical Trial Systematic Review DOI Creative Commons

Guilherme Lopes de Oliveira Pagotto,

Livia Maria Oliveira dos Santos,

Najwa Osman

и другие.

Antioxidants, Год журнала: 2024, Номер 13(6), С. 651 - 651

Опубликована: Май 27, 2024

Alzheimer’s disease (AD) is a stealthy and progressive neurological disorder that leading cause of dementia in the global elderly population, imposing significant burden on both society. Currently, condition treated with medications alleviate symptoms. Nonetheless, these drugs may not consistently produce desired results can serious side effects. Hence, there vigorous pursuit alternative options to enhance quality life for patients. Ginkgo biloba (GB), an herb historical use traditional medicine, contains bioactive compounds such as terpenoids (Ginkgolides A, B, C), polyphenols, organic acids, flavonoids (quercetin, kaempferol, isorhamnetin). These are associated anti-inflammatory, antioxidant, neuroprotective properties, making them valuable cognitive health. A systematic search across three databases using specific keywords—GB AD dementia—yielded 1702 documents, selection 15 clinical trials synthesis. In eleven studies, GB extract/EGb 761® was shown improve function, neuropsychiatric symptoms, functional abilities types. four however, were no differences between GB-treated placebo groups. Significant improvements observed scores obtained from Mini-Mental State Examination (MMSE), Short Cognitive Performance Test (SKT), Neuropsychiatric Inventory (NPI). While majority synthesized show has promising potential treatment conditions, more research needed determine optimal dosages, effective delivery methods, appropriate pharmaceutical formulations. Furthermore, thorough assessment adverse effects, exploration long-term implications, investigation into drug interactions critical aspects must be carefully evaluated future studies.

Язык: Английский

Процитировано

10